Tuberculosis continues to become more resistant to existing drug regimens resulting in a need for constant innovation on the part of drug researchers. In an article published by Medicalxpress.com which can be found here, researchers are reported to have found a chemical alteration that makes fluoroquinolones, an existing group of TB-fighting drugs, more effective against [...]
The Stop TB Partnership is today launching the online consultation into the first public draft of the Global Plan to Stop TB 2016-2020. The consultation process is open to everyone and, will run from 10 June to 10 August 2015.
A supplement dedicated to TB drug development appears in the Journal of Infectious Diseases Volume 211, June 15, 2015. Topics include nonclinical models of TB drug development, PKPD and dose response, drug metabolism and interactions, and special populations.
Researchers at Johns Hopkins University School of Medicine have shown that heart medication, Verapamil administered in combination with Bedaquline lowers the toxicity of the TB drug without altering its efficacy.
We invite you to join us for the Stop TB Partnership Working Group on New Drugs’ Annual Meeting 2014 at AC Hotel Barcelona Forum, Barcelona, Spain, on Wednesday, Oct. 29th from 15:00 to 19:00.
A new study published by Dr. Kyu Rhee’s laboratory at the Weill Cornell Medical College details a potential mechanism driving Mycobacterium tuberculosis’ intrinsic resistance to antibiotics.
Dr. Iwao Ojima is a Distinguished Professor and Director of the Institute of Chemical Biology and Drug Discovery at Stony Brook University. In this interview, Dr. Ojima discusses the work his lab has been doing on tri-substituted benzimidazole compounds that inhibit TB growth.
The drug SQ109, developed by Sequella for the treatment of tuberculosis, blocks key biochemical pathways in bacteria, fungi, and parasites. Its range and ability to inhibit multiple targets, makes SQ109 an attractive broad-based antimicrobial compound that also reduces the likelihood of resistance developing in bugs.
Researchers at EPFL and the Bach Institute in Moscow have discovered an antibiotic effective against sensitive and MDR-tuberculosis. With support from EPFL, the researchers have created Innovative Medicines for Tuberculosis (iM4TB), an organization to help usher the new antibiotic to market.
This week we highlight a study by Richard E. Lee et al showing that semisynthetic antibiotic, spectinamides, is effective against drug sensitive and resistant tuberculosis. Additional links related to this study and general TB R&D are included.